Clinical Trial · NCT02902757

Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT

Overview

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

N/A

Contacts

Soosan Roodbari

sroodbari@mednet.ucla.edu

310 794-1596

ClinicalTrials.gov

NCT02902757

Drug / Compound

Isotope(s):

Target(s):

Eligibility

Inclusion

Intention to start therapy
Patients with histologically proven high grade glioma

Exclusion

Inability to give written consent
Severe psychiatric illness
Breast feeding / pregnancy

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…